What is the role of PLD5 in the regulation of in ovarian cancer?
Best insight from top research papers
PLD5, also known as ENTPD5, plays a crucial role in ovarian cancer (OC) progression. Research indicates that ENTPD5 expression is significantly elevated in OC tissues, correlating with advanced clinical stage and metastasis . Knockdown of ENTPD5 in serous ovarian cancer (SOC) cells leads to inhibited proliferation, migration, and activation of the GRP78/p-eIF-2α/CHOP pathway, suggesting its involvement in endoplasmic reticulum stress (ERS) and highlighting ENTPD5 as a potential therapeutic target for SOC treatment . This demonstrates the importance of ENTPD5 in promoting the growth and metastasis of OC, emphasizing its potential as a target for therapeutic interventions in ovarian cancer.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| ENTPD5 knockdown inhibits tumor growth and metastasis in serous ovarian cancer by regulating the GRP78/p-eIF-2α/CHOP pathway, suggesting a potential therapeutic target for ovarian cancer treatment. | |
8 Citations | FGD5-AS1 regulates ovarian cancer by targeting miR-142-5p, which in turn affects PD-L1 expression, indicating a role for FGD5-AS1 in the regulation of PD-L1 in ovarian cancer. |
| Inactivation of Wnt-LRP5 signaling suppresses proliferation and migration of ovarian cancer cells, highlighting LRP5's crucial role as a potential therapeutic target in ovarian cancer. | |
| Not addressed in the paper. | |
| Not addressed in the paper. |
Related Questions
What is the relationship between molecular classification of ovarian cancer and Primary peritoneal carcinoma?4 answersThe molecular classification of ovarian cancer has shed light on the understanding of different subtypes of this disease. High-grade serous carcinomas (HGSC) have been categorized into distinct molecular subtypes such as Mesenchymal, Immunoreactive, Proliferative, and Differentiated, each with unique biological features and clinical implications. On the other hand, Primary peritoneal carcinoma (PPC) has been debated regarding its classification, sometimes being considered similar to ovarian cancer or as a distinct entity with its own characteristics. Molecular profiling studies have shown subtle differences between PPC and ovarian cancer, such as variations in patterns of genetic alterations and differences in patient outcomes. Despite similarities, PPC patients have been noted to have a shorter survival period compared to ovarian cancer patients, emphasizing the need for further research and tailored therapeutic approaches.
Hormones of ovarian?5 answersHormones of the ovary, such as progesterone and 17β-estradiol, have been shown to have effects on memory functions and cognitive aging. These hormones have also been found to play a role in the regulation of mammary stem cells in the breast, which may be linked to the development of breast cancer. In terms of ovarian cancer, circulating levels of gonadotropins and androgens have been associated with an increased risk, while gonadotropin-releasing hormone and progesterone may be protective factors. Hormonal therapy has been evaluated in clinical trials for ovarian cancer, but with modest efficacy and few side effects. Overall, hormones of the ovary have been found to have significant effects on various aspects of health and disease, including memory, cognitive aging, breast cancer, and ovarian cancer.
What is the molecular mechanism by which ASF1B, ALDH1A3, FGR, CKS1B, and ALOX5AP contribute to ovarian cancer progression?5 answersASF1B, ALDH1A3, FGR, CKS1B, and ALOX5AP have been identified as molecular contributors to ovarian cancer progression. ASF1B is overexpressed in ovarian cancer and promotes cell proliferation, migration, and invasion through activation of the Wnt/β-catenin signaling pathway. ALDH1A3 is also overexpressed in ovarian cancer and is associated with poor prognosis. It promotes cancer stem cell-like properties and contributes to chemoresistance. FGR is involved in the epithelial mesenchymal transition (EMT) process in ovarian cancer, and its suppression decreases EMT progression. CKS1B is upregulated in ovarian cancer and promotes cell proliferation and migration. ALOX5AP is specifically expressed in ovarian tumor samples and contributes to ovarian cancer progression and tumorigenesis. These molecular mechanisms provide potential therapeutic targets for managing ovarian cancer.
What is the role of CLDN5?5 answersCLDN5 plays a crucial role in various biological processes. It is involved in the formation of tight junctions in epithelial cells and is associated with tumor metastasis, the tumor microenvironment, and immunotherapy in multiple types of cancer. In the blood-brain barrier (BBB), CLDN5 is expressed in endothelial cells and helps maintain the brain microenvironment by limiting the diffusion of ions and solutes. CLDN5 is also important for the integrity of the BBB, and its decline can increase the risk of developing neuropsychiatric disorders, epilepsy, brain calcification, and dementia. In podocytes, CLDN5 regulates podocyte function and restricts WNT signaling in the kidney. Pathogenic variants in CLDN5 have been associated with a neurodevelopmental disorder characterized by disruption of the blood-brain barrier and impaired neuronal function. Additionally, a specific mutation in CLDN5 has been linked to alternating hemiplegia with microcephaly, suggesting a channelopathy in the blood-brain barrier.
What's the role of calcium channels in ovarian cancer?4 answersCalcium channels play a significant role in ovarian cancer. Increased expression of voltage-gated and epithelial sodium channels has been detected in ovarian cancer cells and tissues, contributing to cancer proliferation and invasion. Calcium channel blockers have been found to target ovarian cancer stem cells, inhibiting their sphere formation, viability, and proliferation, and inducing apoptosis. Imbalances in calcium transport and regulation have been implicated in ovarian cancer progression, with various calcium channel proteins being involved, such as inositol trisphosphate receptors, ryanodine receptors, and transient receptor potential channels. Calcium channel protein activators have been shown to inhibit the proliferation of ovarian cancer cells, with a dose-dependent effect, suggesting the importance of calcium ions in promoting cell proliferation and regulating apoptosis. Additionally, CACNA1C, a voltage-dependent calcium ion transmembrane channel, has been identified as a potential prognostic predictor for overall survival in ovarian cancer patients.
Which GPCR are know to be involved in ovarian cancer progression?5 answersG protein-coupled receptor 56 (GPR56) has been demonstrated to be involved in ovarian cancer progression. Regulator of G-protein signalling 10 (RGS10) is another GPCR that is associated with chemoresistance and cancer progression in ovarian cancer. Leucine-rich alpha-2-glycoprotein 1 (LRG1) has also been implicated in the progression and metastasis of ovarian cancer. Platelet-derived growth factor receptor (PDGFR)α and its ligands have been found to be expressed in ovarian cancer cells, suggesting the presence of an autocrine loop that promotes cancer growth and spread. Lysophosphatidic acid (LPA) and its GPCR receptors are aberrantly expressed in ovarian cancer and play a role in promoting survival, proliferation, adhesion, migration, and invasion of ovarian cancer cells.